JP2014521662A - ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド - Google Patents

ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド Download PDF

Info

Publication number
JP2014521662A
JP2014521662A JP2014523105A JP2014523105A JP2014521662A JP 2014521662 A JP2014521662 A JP 2014521662A JP 2014523105 A JP2014523105 A JP 2014523105A JP 2014523105 A JP2014523105 A JP 2014523105A JP 2014521662 A JP2014521662 A JP 2014521662A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
heterocycloalkyl
haloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521662A5 (enExample
Inventor
ジェー． ホジェンカンプ，ダーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2014521662A publication Critical patent/JP2014521662A/ja
Publication of JP2014521662A5 publication Critical patent/JP2014521662A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2014523105A 2011-07-29 2012-07-30 ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド Pending JP2014521662A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513059P 2011-07-29 2011-07-29
US61/513,059 2011-07-29
PCT/US2012/048816 WO2013019711A2 (en) 2011-07-29 2012-07-30 NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS

Publications (2)

Publication Number Publication Date
JP2014521662A true JP2014521662A (ja) 2014-08-28
JP2014521662A5 JP2014521662A5 (enExample) 2015-09-17

Family

ID=47629869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523105A Pending JP2014521662A (ja) 2011-07-29 2012-07-30 ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド

Country Status (5)

Country Link
US (1) US20140148412A1 (enExample)
EP (1) EP2736919A4 (enExample)
JP (1) JP2014521662A (enExample)
CA (1) CA2843436A1 (enExample)
WO (1) WO2013019711A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502891A (ja) * 2015-01-26 2018-02-01 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
JP2024114787A (ja) * 2016-07-11 2024-08-23 セージ セラピューティクス， インコーポレイテッド Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA40498A (fr) 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
DK3812392T3 (da) 2015-07-06 2025-07-21 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
DK3529257T3 (da) 2016-10-18 2023-08-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
US12139508B2 (en) * 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
MX2020008182A (es) * 2018-02-11 2020-09-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos.
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US12215126B2 (en) * 2020-05-21 2025-02-04 Brigham Young University Cationic steroidal antimicrobial compounds with endogenous groups
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313809A (en) * 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
WO1996016076A1 (en) * 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
WO2007108002A2 (en) * 2006-03-23 2007-09-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of digitalis-like compounds in the treatment of affective disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313809A (en) * 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
WO1996016076A1 (en) * 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
WO2007108002A2 (en) * 2006-03-23 2007-09-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of digitalis-like compounds in the treatment of affective disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.G.WERMUTH編, 『最新 創薬化学 上巻』, JPN6014041942, 15 August 1998 (1998-08-15), pages 235 - 271, ISSN: 0003360476 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502891A (ja) * 2015-01-26 2018-02-01 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
JP2020189848A (ja) * 2015-01-26 2020-11-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
JP2024114787A (ja) * 2016-07-11 2024-08-23 セージ セラピューティクス， インコーポレイテッド Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
JP7821842B2 (ja) 2016-07-11 2026-02-27 セージ セラピューティクス， エルエルシー Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法

Also Published As

Publication number Publication date
US20140148412A1 (en) 2014-05-29
CA2843436A1 (en) 2013-02-07
EP2736919A2 (en) 2014-06-04
WO2013019711A3 (en) 2013-04-04
WO2013019711A2 (en) 2013-02-07
EP2736919A4 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
EP2736919A2 (en) NOVEL 17ß-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
JP7269911B2 (ja) 向神経活性ステロイド、組成物、及びその使用
EP2215049B1 (en) P2x3, receptor antagonists for treatment of pain
JP4606408B2 (ja) 選択的グルココルチコイド受容体調節物質としての１７−カルバモイルオキシコルチゾル誘導体
JP4054369B2 (ja) オルト置換アリールまたはヘテロアリールアミド化合物
EP2758050B1 (en) Acyclic cyanoethylpyrazoles as janus kinase inhibitors
EP2137181B1 (en) Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
JP7212142B2 (ja) Ｈｐｋ１阻害剤およびその調製方法と応用
WO2007116866A1 (ja) ヘテロ化合物
CA2570780C (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
CN104136452A (zh) 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
BR112018005861B1 (pt) Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos
JP2010504913A (ja) 炎症及び免疫関連使用のための縮合環化合物
JP5897186B2 (ja) Ｐｇｄｓ阻害剤としてのフェニルオキサジアゾール誘導体
JP2021512909A (ja) ステロイド系誘導体モジュレーター、その製造方法及び応用
CA3020287A1 (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP7664359B2 (ja) １５β－［３－プロパンアミド］－置換エストラ－１，３，５（１０）－トリエン－１７－オン化合物および１７β－ヒドロキシステロイドデヒドロゲナ－ゼの阻害に使用するためのそれらの１７－オキシム
CA3020310A1 (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP2020023512A (ja) Ｓ１ｐ３アンタゴニスト
CN103298807A (zh) 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
JP2020519651A (ja) アミン又は（チオ）アミド含有ｌｘｒモジュレーター
JP2012501334A (ja) 置換アミノチアゾール誘導体、医薬組成物、および使用の方法
WO2019241796A1 (en) Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma
TW201136922A (en) New oxadiazole derivatives
CN120607578A (zh) 17β-HSD1抑制剂化合物、药物组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170307